JX10

DRUG2 trials

Sponsors

Corxel Pharmaceuticals Co. Ltd., Corxel Pharmaceuticals

Conditions

Acute Ischemic StrokeAcute ischemic stroke

Phase 2

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

RecruitingNCT06990867

Corxel PharmaceuticalsAcute Ischemic Stroke

Start: 2025-05-15End: 2029-12-31Target: 740Updated: 2026-03-13

Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION) A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Phase 2 3 Study to Evaluate the Efficacy and Safety of JX10 in Acute Ischemic Stroke with Late Presentations

RecruitingCTIS2024-519521-37-01

Corxel Pharmaceuticals Co. Ltd.Acute ischemic stroke

Start: 2025-07-30Target: 287Updated: 2025-10-21